LoadingLoadingLoadingNet selling: insiders sold $1.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $17K to $80K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Citadel
$156.7M
added
Sells/Trims (2)
Millennium
$90.6M
sold
Millennium
$39.5M
trimmed
Top-trader positions in RVTY could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Jul 27, 2026
Period ending
Jul 5, 2026
Earnings per share
$1.23 expected
Estimates as of Oct 23, 2026
EPS expected
$1.28 to $1.33
Revenue expected
15 analysts
Last 30 days
Analysts raising estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jul 5, 2026 | Jul 27, 2026 | $1.18 / $1.23Alpha Vantage | -4.07% miss | $729.7M No estimateSEC filing | Unavailable |
| Apr 5, 2026 | May 5, 2026 | $1.06 / $1.01Alpha Vantage | +4.95% beat | $711.1M No estimateSEC filing | Unavailable |
| Dec 31, 2025 | Feb 2, 2026 | $1.70 / $1.58Alpha Vantage | +7.59% beat | $772.1M No estimate | Unavailable |
| Sep 28, 2025 | Oct 27, 2025 | $1.18 / $1.14Alpha Vantage | +3.51% beat | $698.9M No estimateSEC filing | Unavailable |
| Jun 29, 2025 | Jul 28, 2025 | $1.18 / $1.14Alpha Vantage | +3.51% beat | $720.3M No estimateSEC filing | Unavailable |
| Mar 30, 2025 | Apr 28, 2025 | $1.01 / $0.95Alpha Vantage | +6.32% beat | $664.8M No estimateSEC filing | Unavailable |
| Dec 31, 2024 | Jan 31, 2025 | $1.42 / $1.38Alpha Vantage | +2.90% beat | $729.4M No estimate | Unavailable |
| Sep 29, 2024 | Nov 4, 2024 | $1.28 / $1.13Alpha Vantage | +13.27% beat | $684.0M No estimateSEC filing | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $698.9M | $772.1M | $711.1M | $729.7M |
| Cost of what it sold | $324.3M | $433.9M | $323.5M | $312.8M |
| Gross profit | $374.6M | $338.1M | $387.7M | $416.9M |
| What it spent | ||||
| Research and development | $50.8M | $58.2M | $57.9M | $49.0M |
| Sales and admin | $241.9M | $251.7M | $253.9M | $280.0M |
| Other operating costs | — | -$83.5M | — | — |
| Total operating expenses | $292.7M | $226.4M | $311.8M | $327.6M |
| What was left | ||||
| Operating profit | $81.9M | $111.7M | $75.9M | $89.3M |
| Interest on debt | $22.8M | $23.5M | $24.7M | $23.0M |
| Profit before tax | $55.7M | $91.6M | $50.0M | $63.5M |
| Tax | $8.5M | -$6.8M | $9.1M | $10.1M |
| Net profit | $46.7M | $98.4M | $40.7M | $51.8M |
| EBITDA | $180.5M | $218.2M | $179.8M | $188.6M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Citrini Research Names Charles River, Revvity in AI Drug Thesis
Leans bullishOct 20Revvity Launches AI-First Platform to Coordinate Lab Workflows from Discovery to Manufacturing
NeutralOct 20Revvity Inc. stock outperforms competitors despite losses on the day
NeutralOct 19J.P. Morgan Maintains Revvity(RVTY.US) With Hold Rating, Raises Target Price to $155
Leans bullishOct 18Earnings Date Could Be A Game Changer For Revvity (RVTY)
NeutralOct 17Earnings Date Could Be A Game Changer For Revvity (RVTY)
NeutralOct 17RVTY: Recovery Looks More Credible, But AI Demand And Margin Gains Still Look Priced In
NeutralOct 17Revvity Inc. stock underperforms Friday when compared to competitors
Leans bearishOct 1611 macro signals shaping RVTY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results